Cure My Disease

Don't miss your cure!

 Log in / Sign up

COVID-19 prevention study in kidney patients pulled before it began

NCT ID NCT05110651

Prevention Sponsor: Nicholas Carlson Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if hydroxychloroquine could prevent COVID-19 hospitalizations in adults on dialysis for kidney failure. It was designed as a randomized trial but was withdrawn before enrolling any participants. No results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Expected to start

Apr 2020

An estimate. Start dates often move.

Finished

Oct 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients ≥18 years on chronic dialysis due to end-stage renal disease. * Competence to understand the study rationale, including potential risks and benefits associated with treatment, necessary for written informed consent. Exclusion Criteria: * Prior verified SARS-CoV-2 infection. * Hypersensitivity reaction to chloroquine, hydroxychloroquine or 4-aminoquinolines * Electrocardiogram with QTc (Bazett's formula) \> 450 ms in males and 460 ms in females * Patients reliant on digoxin or amiodarone treatment * Pre-existing psoriasis * Any pre-existing maculopathy with vision reduction * Prior sensorineural hearing loss * Pre-existing severe liver insufficiency (spontaneous international normalized ratio \>1.5 within the last year) * Pre-existing epileptic disease requiring anti-epileptic medication * Pregnancy or lactation * Insurmountable Language Barrier * Participation in other ongoing intervention trials investigating COVID19-related outcomes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 End stage renal disease

Contacts and locations

Locations

  • Herlev Hospital

    Herlev, Herlev, 2730, Denmark

  • North Zealand Hospital

    Hillerød, Hillerød, 3400, Denmark

  • Rigshospitalet

    Copenhagen, Copenhagen, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.